RxDoctor Payments DataLook up a doctor →

Adam Forman, MD

Internal Medicine · Southfield, MINPI 1992094296

Payments from drug & device makers

$524,094in general payments, 2019–2025

Across 492 payments — averaging $1065.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$195K
  • Seagen Inc.$99K
  • Incyte Corporation$65K
  • AstraZeneca$35K
  • Genentech USA, Inc.$35K
  • Genmab U.S., Inc.$17K
  • plus $77K from 41 others

What the payments were for

  • Consulting fees$89,07320%
  • Speaking & faculty fees$326,13472%
  • Travel & lodging$26,8536%
  • Food & beverage$9,8112%
  • Education$770%
  • Other$6980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$524,094 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$132,358
Medicare patients
450
Services billed
1,193

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide34$698,246
RevlimidLenalidomide31$674,894
ImbruvicaIbrutinib31$500,145
TagrissoOsimertinib Mesylate29$480,567
JakafiRuxolitinib Phosphate24$428,649
VerzenioAbemaciclib23$343,113
Lenalidomide21$329,502
BrukinsaZanubrutinib26$291,175
CabometyxCabozantinib S-Malate12$284,044
CalquenceAcalabrutinib Maleate18$180,635
XtandiEnzalutamide24$173,693
VenclextaVenetoclax17$102,670
InqoviDecitabine/Cedazuridine18$96,038
EliquisApixaban99$82,667
XareltoRivaroxaban22$17,460

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$195,095$698,24634 claims
Bristol Myers SquibbRevlimid$11,276$674,89431 claims
AstraZenecaTagrisso, Calquence$35,357$661,20247 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$616$500,14531 claims
Incyte CorporationJakafi$65,339$428,64924 claims
Lilly USA, LLCVerzenio, Olanzapine$55$343,41843 claims
Exelixis Inc.Cabometyx$2,590$284,04412 claims
Astellas Pharma US IncXtandi$671$173,69324 claims
AbbVieVenclexta$154$102,67017 claims
Taiho Oncology, Inc.Inqovi$37$96,03818 claims
PfizerEliquis$97$82,66799 claims
Johnson & JohnsonXarelto$6,595$17,46022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →